K.J. Harrison & Partners’s 10x Genomics TXG Stock Holding History

K.J. Harrison & Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,060	Closed	-$226K	–	206
2023 Q2	$226K	Hold	4,060	–	–	0.04%	194
2023 Q1	$227K	Hold	4,060	–	–	0.05%	191
2022 Q4	$200K	Buy	+4,060	New	+$133K	0.04%	195
2022 Q2	–	Sell	-4,310	Closed	-$328K	–	307
2022 Q1	$328K	Hold	4,310	–	–	0.05%	199
2021 Q4	$643K	Buy	4,310 +10	+0.2%	+$1.53K	0.09%	182
2021 Q3	$630K	Sell	4,300 -3,500	-45%	-$601K	0.09%	187
2021 Q2	$1.53K	Buy	7,800 +2,050	+36%	+$371K	0.16%	127
2021 Q1	$1.04M	Sell	5,750 -8,000	-58%	-$1.38M	0.16%	146
2020 Q4	$1.95M	Buy	13,750 +1,000	+8%	+$145K	0.32%	107
2020 Q3	$1.59M	Hold	12,750	–	–	0.33%	104
2020 Q2	$1.14M	Buy	+12,750	New	+$993K	0.31%	96

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

K.J. Harrison & Partners's TXG Position: Q3 2023 in Review

K.J. Harrison & Partners sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 4,060 shares — an estimated $226K sold.

K.J. Harrison & Partners first reported a position in TXG in Q2 2020 and held it in 11 quarters. The position peaked at $1.95M in Q4 2020. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

K.J. Harrison & Partners reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
K.J. Harrison & Partners sold 4,060 10x Genomics shares in Q3 2023, an estimated $226K.
K.J. Harrison & Partners first reported a position in 10x Genomics in Q2 2020 and held it in 11 quarters.
K.J. Harrison & Partners's 10x Genomics position peaked at $1.95M in Q4 2020.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on K.J. Harrison & Partners's 13F filing for Q3 2023, filed 31 Oct 2023.